A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults with Asthma - ARTEMISIA

Study identifier:D8210C00005

ClinicalTrials.gov identifier:NCT06435273

EudraCT identifier:N/A

CTIS identifier:2023-510291-32-00

Recruiting

Official Title

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults with Asthma

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD4604, Placebo to AZD4604

Sex

All

Estimated Enrollment

48

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 05 Aug 2024
Estimated Primary Completion Date: 12 Aug 2026
Estimated Study Completion Date: 12 Aug 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria